Research News
View articles by month and year
-
Weekly Low-Dose Taxol Offers Same Benefits as Higher Dose Every Two Weeks with Different Side Effects
A study has found that getting Taxol (chemical name: paclitaxel) at a lower dose weekly offers the same benefits as getting a higher dose every 2 weeks.
-
Ginger May Help Ease Nausea Immediately After Chemotherapy
A small study suggests that adding ginger to standard anti-nausea medicines can reduce nausea in women diagnosed with advanced-stage breast cancer immediately after chemotherapy more than the anti-nausea medicines alone.
-
Chemo During Pregnancy Appears Safe for Mother and Child
A study supports other research that suggests chemotherapy during pregnancy doesn't have harmful effects on the baby.
-
Afinitor Before Surgery Doesn’t Help Treat HER2-Negative Breast Cancer
Research has found that adding Afinitor to paclitaxel didn't improve the response to neoadjuvant treatment with paclitaxel in women diagnosed with advanced-stage, HER2-negative breast cancer.
-
Xeloda Doesn’t Seem to Reduce Recurrence Risk
A new study shows that the risk of recurrence is the same whether or not Xeloda was added to a standard adjuvant chemotherapy regimen for early-stage breast cancer with a high risk of recurrence.
-
Chemo During Pregnancy Doesn’t Harm Baby
New research supports other studies that suggest that chemotherapy during pregnancy doesn't have harmful effects on the baby.
-
Taxotere Better Than Fluorouracil in Chemo Regimen After Surgery for Early-Stage Disease
Chemotherapy that included Taxotere offered slightly better results than a regimen that included 5-FU for women diagnosed with early-stage breast cancer that hadn't spread to the lymph nodes, but Taxotere was more likely to cause serious side effects.
-
Giving Chemo Medicines Sequentially May Have Advantages
Treating early-stage breast cancer with two chemotherapy medicines followed by a third seems to have some advantages compared to giving two or three medicines at the same time, but may cause more severe side effects.
-
Herceptin Plus Chemotherapy Without Anthracycline Effective
The latest results from the BCIRG-006 trial found that Herceptin plus chemotherapy that didn't include an anthracycline was as effective as Herceptin plus chemotherapy that did include an anthracycline for women diagnosed with HER2-positive, early-stage breast cancer.
-
Research Continues to Show Benefit of Chemotherapy After Breast Cancer Surgery
Research suggests that post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer that had spread to the lymph nodes who got adjuvant chemotherapy AND adjuvant hormonal therapy had a lower risk of recurrence and were more likely to be alive than women who got only hormonal therapy. The study also showed that starting hormonal therapy after chemotherapy was done was better than giving hormonal therapy and chemotherapy at the same time and that a genetic test can help figure out if women diagnosed with early-stage, hormone-receptor-positive breast cancer that has spread to the lymph nodes will benefit from adjuvant chemotherapy.
